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Although both Intravenous dlpyridemotr and adenosine have been
wand to produce coronary vasof'ailnion during cardiac imaging.
the relative potency of the commonly ad dJared doses
41
thorn agent has wit been avaiwahd, Accordlagly, The curonar
and syslgtk henrodynsmir effects of intravenous adenosine
(140 /,eg7tg per w>s) and L'ttraveaon dipyrktoamle I0.% nrg/k
over 4 mini were compared with a maximally dilating dose of
letrsoraaary papavertue in 15 pnlknts
. Coronary blood flow
responses were assessed using a Doppler cuihnn in a no0stenotic
coronary artery
. The protocol was disconfinued in v- primes
I:ecimse of transient asymplomatic atrioventricular (AV) block
during adenosine Infusion
.
The mean had rate increased more with adenosine III ± 9
Mxtslminl and dipyridamuk (II t 7 hatdmis) than with pa-
Faverlne (4 a 3 heatstmin, p < 0.05 vs. adenosine and papa-
heel. The man arterial pressure decreased ksa with dipyridamnk
(-70 t 3 mm Hel and papaverinw I-9 e 4 mm Hill than nith
a alnsine (-16 t 5 mm Mg, p < 0 .01 vs, dipyrntamot and
pasaverine). Toro pealdresl coronary blow flowsthxity ratio was
Pharmacologic coronary vasodilation with intravenous do-
pyridamoie has been reported to be of value in the noninva-
sive d'agnosee of corollary artery disease by several modal-
ities. including thalliurs-201 myocardial perfusion imaging
(1 .2). two-dimensional echocardiography 11 .4) and pwii,nn
-fission
tomography (5 .6) . Dipyridamole appears ce pro-
duce coronary vaserdilation by elevating lntarstitial adeoo ,
sine concentration through blockade of cellular uptake of
adenosine . The direct administration of adenosine to pro-
duce intense Coronary dilation in humans Was recently
studied by Wilson ct al . 171, Their dose-ranging study of
intravenous adenosine administration showed that infusion
at a rate of (49 agkg per min resulted in an increase in
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greater with papaverine (3 .9 ± 1 .1) than witb adenosiue (3.4 t
1 .2,p s 0,115 vs, papaverineiordipyridaneolelRl 2 1 .2,p< 0.01
vs- papaverine) . A larger decrease In awvoary resistance ae
measured by the coronary vascular resistance Index Occurred with
papa.erine 10.25 ± 0.06) and adenodoe -10.26 2 0.09) that with
dipvridamolr 1021 2
0
.10, p < 0
.01 ns, papaverltte, p < 0,05 vs,
adenososel
. The maximal coronary blood Sow velocity was
reached ranre quickly after The start of adenosine infusion (55 t
34 s1 than after the stare o dipyridamole infusion (287 ± 10? s,
p < 4
.01)01. The pensimat coronary artery diameter was an .
changed during dipyridamok or adenosise infusion . Thus, the
sasoditatdr ploeacy of adenosine was greater Than that of dipyr.
idanwle wises changes in coronary
redastanee
were considered,
though increases in flow were similar with it* two agents. The
rapid onset of action of adraoshtecoenpared with
that otdipyrida-
wrrok may allow a reduction in the duration of diagnostic studies.
The incidence or AV block during adenosine infusion requires
evaluation in larger stsdies.
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coronary blood flow that was comparable with that induced
by . vrsenronary, papaverinc in the majority of patients . Two
studies i8 .9) using this dose of adenusine with thallium-201
sci nt;grphy have reported a sensitivity of 83 k and 92% with
a specificity of94% and 100 %_ respectively . far detection of
ubs!ruciive coronary artery disease .
Though both adenosine and dipyridamole are suitable for
production of coronary vasodilation during cardiac imaging
procedures, the coronary hemodynamic effects of these
agents given in the commonly used doses have not been
directly compared . Accordingly, the purpose of this study
was to evaluate the relative coronary vasodilator potency of
intravenous adenosine given at 140 yeg/kg per min and
iottavenous dipyridamok given at the standard dose of
U-56 mgtkg over 4 min . These agents were compared with n
maximally dilating dose of intracoronary papaverine (10).
Methods
Study patients. Patients undergoing elective coronary
arteriography for the evaluation of chest pain were consid-
ered for study if angiography revealed an unobstructed
n, a5-ta97Alrf3.na
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coronary artery suitable for eannulation with a coronary
Doppler catheter . Exclusion criteria included congestive
heart failure, unstable myocardial ischemia, obstructive pul-
monary disease, second or third degree atrioventrieular
(AV) hick and treatment with oral dipyridamole or then-
phylline preparations . Fifteen patients . seven men and eight
women (mean age 54.1 ± 10 .4 years ± SD), were enrolled in
coronary flow studies . Angiographically normal coronary
arteries were present in seven patients (six women, one
man!, single-vessel coronary disease narrowing the luminal
diameter by <50% was present in six (one woman, five men)
and single-vessel disease with =50% diameter stenosis was
present in two (one woman, one man). The coronary artery
judged to he most easily cannulnted by the coronary Doppler
catheter was inten-ugated : the left anterior descending artery
was studied in seven patients, the left circumflex artery in
three, the right coronary artery in three and the left main
artery in two . The research protocol was approved by the
University of Iowa Institutional Review Board, and written
informed consent for the research protocol was obtained
from each patient before cardiac catheterization .
Coronary blood flow velocity measurement. An intracor-
onary Doppler catheter was used to measure blood flow
velocity in 14 patients (111 . A 7F or 8F coronary guiding
catheter (USCI Bard or Shiley) was positioned at the co,o-
nary ostium and a 0 .014 i,^, . (0.036 cm) coronary angioplasty
guide wire (USCI Bard) was advanced into the coronary
artery to be studied. A 3F 20 MHz coronary Doppler
catheter (NuMed) was advanced over the guide wire into the
proximal vessel. An 8F left 3udkins catheter with a tip-
mounted Doppler crystal (Cordis) was used to measure
coronary blood flow velocity in one patient . Coronary blood
flow velocity changes measured with this design are compa-
rable with those measured with an intracoronary Doppler
catheter 1121 . The zero-cross method Doppler veloeimeter
(11) (University of Iowa Hospitals and Clini, - 1) was range-
gated to maximize the amplitude of the mean coronary blood
flow velocity signal . Values for phasic and mean coronary
blood flow velocity 1kHz shift), mean arterial pressure
obtained from the guiding catheter, heart rate and the
electrocardiogram IECGI were continuously recorded on a
multichannel recorder .
Assessment of coronary vasodilator potency . Coronary
vasodilator potency was assessed by calculating the quotient
of the peak mean blood flow velocity during each hyperemic
stimulus (kHz shift) and the rest mean flow velocity . As a
measure of the change in enronary vascular resistance
during each intervention, a coronary vasculer resistance
index was calculated as the quotient of (mean aortic pressure
at peak blood flow velocity Imm HgI/peak blood flow veloc-
ity IkHz shift)) and (mean aortic pressure at tes' blend flow
velocity/rest blood flow velocity) .
Experimental protocol . Patients were brought to the car-
diac catheterization laboratory in a fasting stare . Methyl-
xanthine-containing foods and beverages were withheld for
?12 h . Antianginal medications were continued . and diaze-
pam or midazolant hydrochloride was given for sedation .
The study was performed wIS min after diagnostic catheter-
iruion and during intravenous infusion of nitroglycerin at
8 ,tftmin to avoid catheter-induced coronary artery spasm
and prevent papaveriue-induced dilation of the proximal
coronary artery (10) .
After measurements of lest heart rate . Mean arterial
pressure and coronary blood flow velocity, 6 to 10 mg of
papaverine hydrochloride (2 mg/ml of 0
.9% saline solution)
was injected through the guiding catheter into the coronary
ostium. To confirm that a dose of papaverine produced
maximal hyperemia, coronary blood flow velocity was re-
corded during adm.ri ;ration of an additional papaverine
dose 2 to 4 mg l u •g er than the previous dose
. When coronary
blood flow velocity and systemic hemodynamics had re-
turned to baseline values, adenosine (Adenoscan. Medco
Research) was infused through the femoral vein at a rate of
140 1aglkg per min for 4 to 5 min . Heart rate, mean arterial
pressure and coronary Wood flow velocity were measured
during the last 30 s of adenosine infusion . After a period of 5
to 10 min, when hemodynarnics had returned to baseline
values, dipyridamole (Persantinc, Boehringer Ingelheim)
was infused through the femoral vein at a rate of 0 .56 mg/kg
over 4 min . Heart rate, mean arterial pressure and coronary
blood flow velocity were measured 4 min after completion of
the dipyridamole infusion, because the peak increase in
coronary flow may be delayed by this interval (I U. Random-
ization of order of drug infusion was impossible because of
the long duration of action of dipyridamole . The experimen-
tal protocol was completed in 13 of 15 patients ; 2 patients
experienced adverse effects and were excluded from the
.study (see Results) .
Evaluation of coronary artery caliber during admteable and
dipyridamok infusions, Because coronary blood flow veloc-
ity is proportional to coronary flow only if coronary caliber
is unchanged . angiographic assessment of coronary diameter
during adenosine and dipyrdamole administration was per-
formed in a separate patient group . Coronary arteriography
with computerized quantitative ennlysis was performed in
five patients (three men and two women, mean age 59.6 t
10 .9 years) with use of the infusion protocols outlined earlier
(including administration of intravenous nitroglycerin) . Artc-
riography was performed with a standardized protocol of
iohexol power injection 4 min after the start of adenosine
infusion and 8 min after the start of dipyridamole infusion .
The diameters of nine proximal segments of angiographically
normal coronary arteries were measured in duplicate with
the Pie Medical Coronary Artery Analysis System (The
Netherlands) (13) .
Data analysis. Data reported are mean values ± SD . Data
were anilyzed using a two-way analysis of variance for
repeated measures or Student's I test for paired data . Sta-
tistical significance was assumed at p < 0
.05
. The signifi-
cance of intergroup differences was assessed using the
Scheffe F test.
race Vor. 18 , 900 2
Au'otI 1991
.49.1-91
Results
Systemic hemodynamlcs (Table 1, Fig, 1) . Mean heart
rates during the control periods preceding administration or
each vasodilator were nearly identical . Mean rate at the time
of peak coronary dilator effect increased with all three drugs,
and the increase was larger with adenosine (I I ± 9 beats!
min) and dipyridamole 111 ± 7 beats/min) than with papav-
erine (4 ± 3 beats/rain). Mean arterial pressures during the
control periods preceding administration of each vasodilator
were nearly identical
. Mean arterial pressure decreased with
all three vasodilatory drugs, and the decrease was larger
with adenosine (-16 a 5 mm Hg) than with dipyrdamole
(-10 a 3 min Hg) and papaverine (-9 ± 4 mm Hg).
Coronary vasodilator potency (Table 1, Fig
. 1 to 4)
. A
representative tracing of coronary blood flow velocity and
arterial pressure during papaverine, adenosine and dipyrida-
mole administration is shown in Figure 2
. The pcak/resl
coronary blood flow velocity ratio was greater with papav-
erine (3 .9 ± LI) than with adenosine (3 .4 -- 1 .2) and
dipyridamole (3 .1 ± 1 .2) (Fig
. 3)
. Comparison of the aden0-
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Effect of k,;rac00onar ; I'apaverine, Intravenous Adenosine anti Intravenous Dipyridamolc oa Coronary amt tivstcmic
Hemodynomic Vanohlcs
Heal Rate ibenIc/mint MAP 1mmH01
nary
n - 13 (-7 hemodyl,mnle studies, n - 9 arteries in 5 pa!ients for aneingraphic ludles .
' p <
0,001 venus preceding control: fp < 0.05 versus papavennri
7p < I
.Ot versus papavedne and dipvridamole
. 4p <
0-to versus papavenne
; ilp
< 0.01 'e
vapaverine .
p < 0
.05
versus adenuane . CRFV - coronary Road
flow unlucky . CVRI - wrenary vascular sesiclaace index ; MAP =mean am•I ia1 presv¢
ws
dlpyridesnole
sine and dipyrdamole floe ; velocity ratios by paired t test
revealed no significant difference (two-nailed, p = 0 .16). The
pcaklrest flow velocity ratio was <75% of' 'he papaverine
response in three patients after adenosine and in five patients
after dipyridamole . The decrease in coronary vascular resis-
tance was larger with papaverine (0 .25 r 0 .06) and adeno-
sine (0 .26 x 0.09) than with dipyridamole (0 .31 •- 0.10) (Fig.
31 . Plots comparing each patient's blood flow velocity and
resistance response after administration of dipyridamole and
adenosine are shown in Figure 4
.
Coronary artery diameter (Table 1) . Neither adenosine
nor dipyridamole produced changes in the diameter of nine
proximal nonstenotic coronary artery segments.
Time course of action. The maximal increase in coronary
blood flow velocity was reached more quickly after the start
of adenosine infusion (55 ± 34 s) than after the start of
Figure 1 . Effect on heart rate (k0) and mean arterial pressure (right)
of mtracoronary papaverine . inlravenou • adenosine and intravenous
dipynd,onole.
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Kg. . 2. A continuous tracing of right coronary anew phasic blood
flow velocity, mean coronary blood flow velocity and mean arterial
pressure during administration of intracoronary l1Cl parsverine,
intravenous (193 adenosine and intravenous dipyridamole
. In this
patient the coronary blood flow responses were similar in magnitude
with all three agents . Coronary blood flow inrparod more quickly
with adenosine than with dipyridamole .
dipyridamole infusion (297
-
101 s, p < 0.00011 . After
termination of adenosine infusion, coronary blood flow
velocity returned to 50% of maximal change Ia 37 ± 18 s and
returned to baseline value in 154 ± 88 s
.
Fgure 3. Effect on ovaklrest coronary blood flow velocity Ilenl ant'
coronary vascatuu
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erine, falravenous adenosine and intravenous dipyddamole .
amrernm dtpyrarrroe.
0.e
Q.a
scent
rwtaLtrw
IrrOarl act
0
pnpnrnrarn Mnea
• porn .uppn ra,.
P ..-.-'-
[ACC.
Vat . la. Nn . 2
MR.,, 1991 :485-91
Adverse effects. Atrioventricular block developed in
three patients in the flow velocity protocol during adenosine
infusion ; the protocol was discontinued in two of these
three. High grade AV block developed in a 40 year old
woman receiving digoxin and propranolol for treatment of
paroxysmal airiRl taehyeardia with rapid ventricular re-
sponse who initially had first degree AV block. Second
degree AV block developed transiently in a 51 year old
man receiving diltiazem
but did not necessitate discontinu-
ation of the protocol. Second degree AV block occurred
in a 68 year old man with ECU evidence of left ventricular
hypertrophy who was receiving no medication . Readminis-
tration of ndenosine to this patient at a dose of 87 Itg/kg per
min
resulted in a coronary blood flow response equivalent
to that of papaverine . and AV block did not recur . None of
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the patients who developed AV block had significant coro-
nary obstruction (>50% diameter slcnosis) . Atrioveniricular
block was asymptomatic in all patients, and resolved
promptly without specific therapy after adenosine infusion
was discontinued.
Discussion
Comparison of adenosine and dipyridamule effects. This
study compared the coronary and systemic hemodynamic
responses produced by the doses of intravenous dipyrida-
mole (0
.56 mg/kg for 4 min) and adenosine (140 frglkg per
min) that hove been recommended for use during cardiac
imaging . These agents were compared with intracoronary
papaverine, which has
been
thought 110) to produce maximal
coronary vAsodilation . The effects of these agents as as-
sessed by the peaklrest coronary blood flow velocity ratio
were larger with papaverine than with adennsine or d ipyrida.
mole . The
flow response tended to be greater with adenosine
than with dipytidamole, but this difference was not statisti .
ally
significant . Coronary
vasodilator
potency was also
assessed by a coronary vascular resistance index . which
incorporates change in arterial pressure
. Using this index,
the coronary vasodilator effect of adenosine was greater than
that of dipyridamole and equivalent to that of papaverine .
Pharmncologic va5odilalion with intravenous dipyrida-
mole has had wide investigative use in the diagnosis of
coronary artery disease and for identification of patients who
arc at high risk for cardiac complications after vascular
surgery (14,15). This agent has proved to be relatively safe
(16) . A potential limitation to the utility of dipyridamole
studies is the failure to achieve maximal coronary vasodilun
tion with the standard dose of 0
.56 mgrkg over 4 min . The
present study confirms previous reports of this limitation
from our laboratory (17) and others (10
.111 . Increased accu-
racy in the diagnosis of coronary artery disease has been
reported with use of high dose dipyridamole regimens
(0
.84 mg/kg total dose) during echocardiography
(4) . How-
ever, achievement of maximal increases in coronary blood
505555 hi AL .
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Fir- 4- Plots comparing the responses of individual patient peakm
rest coronary flow velocity ratios Ikhl and coronary vascular
resistance indexes (right) to intravenous dipyridamotc and intrave-
adenosine in 13 patients . Each dot represents values in one
patient,
flow may not be important for all diagnostic techniques
because radionuclide myocardial perfusion tracer extraction
may reach a plateau at suhmasimal flow rates . Experience
with larger dipyridamole doses is relatively limited and it is
uncertain if the favorable profile of adverse effects reported
with the standard dipyridantule dose will also pertain to high
doses.
Safety . Transient asymptomatic second degree or high
grade AV block developed during adenosine infusion in 3 of
20 patients in the present study . Heart block resolved
promptly after discontinuation of adenosine in all cases .
Atrtuventricular block during adenosine infusion at this or
similar doses has been reported pre,iously, but at a much
tower incidence. Second degree AV
block. occurred in I of 30
patients studied in the catheterization laboratory by
Wilson
et al, 17). In larger series of patients studied during cardiac
imaging protocols, second degree or high grade AV block
developed in 1_ l m'
of 89 patients (S), none of 60 patients (9) .
3,51!9 of 607 patients
(18). 2 .2% of 224 patients ( 19) and 4.5%
of 224 patients (20)
.
The overall incidence of AV block of
approximately 3% appears to be greater than that reported
with standard dose dipyridamule . No significant sequelae of
adenosine-induced AV block have been reported,
The frequency of other adverse effects influences the
clinical utility of pharmacologic coronary vasodilators . In
the current study, administration of parenleral benzodiaze-
pine for sedation during catheterization precluded useful
evaluation of symptoms. Verani et ai. 18) and Nguyen et al.
(9) reported a relatively high incidence of side effects during
adenosine infusion
. 8840 and 83%, respectively . Chest pain .
headache, flushing and dyspnea may occur more often with
adenosine than with dipytidamole (211, although adverse
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effects are typically mild and resolve within I or : min of perform studies with this agent and the duration cal any
discontinuation of adenosine . Given the more extended adverse effects that develop .
duration
of action of dipyndamole than of adenosine, ad-
verse effects may persist longer with this agent and may
require reversal with intravenous aminophylline more fre-
quently .
Potential methodologic limitations. I?xtensive animal
studies validating the coronary Doppler catheter design used
in this study have been published I I11. Changes in coronary
blood flow velocity measured With the Doppler catheter
correlated well with changes in measured limed volume
collections of coronary sinus Mood over a wide range of
coronary blood flow, Identical maximal coronary reac-
ive hyperemia responses were obtained with or without
the catheter in the artery under study . When global
myoardial flow was altered pharmacolegicalle, changes in
coronary blood flow velocity assessed by IN Catheter were
highly correlated with simultaneous measwements of flow
velocity obtained with use of an epicardial Doppler probe
placed in a separate perfusion field . These Wings suggest
that changes in blood flow velocity measured in individual
coronary arteries by the coronary Doppler 'catheter accu-
rately reflect changes in coronary blood flo -
,n .
and that the
catheter does not produce physiologicsdiy detectable ob-
struction
.
Changes in volumetric
flow during an intervention may
nut be accurately reflected by changes in coronary blood
flow velocity if the intervention also alters the coronary
luminal diameter at the site of velocity measurement Quati-
titative coronary angiography revealed no change in the
caliber of proximal nonstenolic coronary segments when
adenosine
or dipyridamole was administered during low
dose nitroglycerin infusion, as during coronary blood flow
Velocity Measurement . Similarly, intracoronary papaverine
administraiob goes not change coronary artery diameter
under these conditions (191. The order of administration of
adenosine and dipyridamole was not randomized in the
prcscnt study . Randomization of drug administration was
not feas'ble given the long duration of the vasodilator action
of dipyndamnle and the possibility of pateatiation of the
subsequent adenosine affect. Finally . because only a single
dose of adenosine and dipyridamole eras slven, the relative
effects of
other dosing regimens cannot be addressed .
Climeal implicatio
:TS . The vasodilator potency of intrave-
nous adenosine was superior to that of intracoronary dipyr-
idamule when coronary resistance changes were considered,
though increases in flow velocity were similar with the two
agents. Transient asymptomatic AV block was observed in 3
of 20 patients with
adenosine but not with dipyridamole. It is
uncertain if the differences between these agents in hemo-
dynamic profile and incidence of adverse effects will trans-
late into differences in the diagnostic utility of techniques
employing phamtacologic coronary vasodilation
. The rapid
onset of action and elimination of adenosine compared with
dipyridamole may reduce both the lime needed to
We (hank me perusanel of the Cardiac Cathatenaation laboratory of the
Gniserdly
of Iowa Hospitals and the Iowa City Veterans Attain Medical
Center far their assistance to performing these studies, Diane Phillips tar
wcmnda asunence and Timothy Hofmeyre for technical assistance .
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